Oral semaglutide (Rybelsus)
Oral peptide GLP-1 agonist · GLP-1 class · oral peptide · Novo Nordisk
Top dose
25 mg
HbA1c reduction
-1.80%
at week 52 · treatment policy
AE discontinuation
7.0%
Status
approved
Pivotal trial
- Trial
- PIONEER PLUS
- Indication
- type 2 diabetes
- Duration
- 52 weeks
- ClinicalTrials.gov
- NCT04707469
- Sponsor
- Novo Nordisk
Notes
PIONEER PLUS (Aroda Lancet 2023): oral semaglutide 25 mg HbA1c -1.8% and 50 mg -2.0% vs 14 mg -1.5%, baseline 9.0%. Higher doses (25/50 mg) approved 2025. Requires fasting administration.